| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | T14; S152; Tp55; TNFRSF7; S152. LPFS2 |
| WB Predicted band size | 29 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human CD27 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CD27抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**: *CD27 Agonists as Emerging Anticancer Therapeutics: Preclinical and Clinical Advances*
**作者**: Roberts PJ 等
**摘要**: 该研究探讨了CD27激动型抗体在癌症免疫治疗中的应用，显示其通过激活CD27共刺激信号增强T细胞抗肿瘤反应，并在黑色素瘤和淋巴瘤的临床前模型中显著抑制肿瘤生长。
2. **文献名称**: *Targeting CD27 in Autoimmunity: Insights from Mouse Models*
**作者**: van Lier RA 等
**摘要**: 研究利用小鼠模型评估CD27抗体在自身免疫疾病中的作用，发现阻断CD27信号可减少致病性T细胞活化，提示其在类风湿性关节炎等疾病中的治疗潜力。
3. **文献名称**: *CD27 Signaling Enhances Antiviral T Cell Immunity during Chronic Viral Infection*
**作者**: Penaloza-MacMaster P 等
**摘要**: 该文献报道CD27抗体通过增强CD8+ T细胞功能改善慢性病毒感染控制，为HIV或HCV等疾病的免疫治疗提供了新策略。
---
以上文献均聚焦于CD27抗体在不同疾病背景下的作用机制及治疗潜力，覆盖癌症、自身免疫病和病毒感染领域。
CD27. a member of the tumor necrosis factor receptor (TNFR) superfamily, is a transmembrane glycoprotein expressed on T cells, B cells, and natural killer (NK) cells. It plays a critical role in regulating lymphocyte activation, differentiation, and survival. CD27 interacts with its ligand CD70. transiently expressed on activated immune cells, to co-stimulate T-cell responses and promote memory cell formation. Dysregulated CD27-CD70 signaling is implicated in autoimmune diseases, chronic inflammation, and cancer, where sustained CD70 expression on tumor cells may drive immune evasion.
CD27-targeted antibodies have emerged as promising immunotherapies. Agonistic anti-CD27 antibodies enhance T-cell activation by mimicking CD70 signaling, potentially boosting antitumor immunity. Conversely, antagonistic antibodies block CD27-CD70 interactions to suppress pathological immune activation in autoimmune conditions. In oncology, CD27 agonists are being explored as monotherapies or combination partners with PD-1/PD-L1 inhibitors to overcome checkpoint inhibitor resistance. Early-phase clinical trials (e.g., varlilumab) demonstrate acceptable safety profiles and preliminary efficacy in solid tumors and lymphomas. Challenges include optimizing receptor engagement without excessive T-cell exhaustion and managing cytokine release syndromes. Additionally, CD27 expression on regulatory T cells complicates its therapeutic modulation, necessitating precise targeting strategies. Research continues to elucidate context-dependent roles of CD27 in immune regulation and refine antibody engineering approaches for clinical translation.
×
